<p>Ikena Oncology（納斯達克股票代碼：IKNA - 獲取免費報告）於週四公佈了其財報。該公司報告本季度每股收益為（$0.06），超出分析師一致預期的（$0.14）$0.08，Zacks 報道。</p>
<p>獲取 <strong>Ikena Oncology</strong> 的提醒：</p>
<h2>Ikena Oncology 股價上漲 4.4%</h2>
<p>週五午盤交易中，納斯達克股票代碼：IKNA 的股票上漲了 $0.06，達到 $1.43。該公司交易了 445,143 股，較其平均交易量 411,726 股有所增加。該公司的 50 日移動平均線為 $1.31，200 日移動平均線為 $1.32。Ikena Oncology 的一年最低價為 $0.97，一年最高價為 $1.94。該股票的市值為 6901 萬美元，市盈率為-2.23，貝塔值為 0.50。</p>
<p>Ikena Oncology 的股票將於 7 月 28 日（星期一）進行反向拆分。1-12 的反向拆分於 7 月 25 日（星期五）宣佈。股東所持股份的數量將在 7 月 25 日（星期五）市場收盤後進行調整。</p>
<h2>分析師評級變動</h2>
<p>另外，Wedbush 在週五的研究報告中將 Ikena Oncology 的目標股價從 $25.00 下調至 $23.00，並對該公司給予 “中性” 評級。</p>
<p><strong>查看我們關於 IKNA 的最新研究報告</strong></p>
<h2>對 Ikena Oncology 的對沖基金看法</h2>
<p>一家對沖基金最近增加了對 Ikena Oncology 股票的持股。高盛集團在第一季度將其在 Ikena Oncology, Inc.（納斯達克股票代碼：IKNA - 免費報告）的持股增加了 62.4%，根據其最近向證券交易委員會提交的 13F 表格。該基金在本季度購買了額外的 29,369 股後，持有 76,464 股該公司的股票。高盛集團在其最近向證券交易委員會提交的文件中顯示，持有 Ikena Oncology 的股份佔 0.16%，價值 98,000 美元。對沖基金和其他機構投資者持有該公司 75.00% 的股份。</p>
<h2>關於 Ikena Oncology</h2>
<p>（獲取免費報告）</p>
<p>Ikena Oncology, Inc 是一家腫瘤學公司，專注於開發針對美國患者的差異化療法，旨在針對癌症生長、擴散和治療抵抗的節點。其主要項目是 IK-930，這是一種內部發現的、口服的、TEAD1 選擇性的 Hippo 通路小分子抑制劑。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Ikena Oncology</li>
<li>消費者可選股票解析</li>
<li>加密懷疑論者仍可通過這些風險限制 ETF 獲得豐厚回報</li>
<li>擁有債券的風險</li>
<li>3 只折扣鋼鐵股票，您今天可以進行定投</li>
<li>什麼是 MACD 指標以及如何在交易中使用它</li>
<li>貝克休斯可能在無人機防禦熱潮中成為意外贏家嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUtOQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUtOQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資$1,000 到 Ikena Oncology 嗎？</h2>
<p>在您考慮 Ikena Oncology 之前，您需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦購買，以便在更廣泛的市場注意到之前...而 Ikena Oncology 並不在名單上。</p>
<p>雖然 Ikena Oncology 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

IKNA

<p>Ikena Oncology（納斯達克代碼：IKNA）報告的季度每股收益為（$0.06），超出市場共識預期的（$0.14）$0.08。公告後，股價上漲 4.4%，至$1.43。高盛將其在該公司的持股增加了 62.4%，而 Wedbush 將其目標價從$25.00 下調至$23.00，維持 “中性” 評級。Ikena 的股票將於 7 月 28 日進行 1 比 12 的反向拆分。對沖基金持有該公司 75% 的股份，反映出強勁的機構投資興趣</p>

<p>Ikena Oncology (NASDAQ:IKNA - Get Free Report) announced its earnings results on Thursday. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.08, Zacks reports.</p>
<div class="lb-trans"><p>Ikena Oncology（納斯達克股票代碼：IKNA - 獲取免費報告）於週四公佈了其財報。該公司報告本季度每股收益為（$0.06），超出分析師一致預期的（$0.14）$0.08，Zacks 報道。</p>
</div><p>Get <strong>Ikena Oncology</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Ikena Oncology</strong> 的提醒：</p>
</div><h2>Ikena Oncology Trading Up 4.4%</h2>
<div class="lb-trans"><h2>Ikena Oncology 股價上漲 4.4%</h2>
</div><p>Shares of NASDAQ:IKNA traded up $0.06 during midday trading on Friday, reaching $1.43. 445,143 shares of the company were exchanged, compared to its average volume of 411,726. The business's fifty day moving average is $1.31 and its two-hundred day moving average is $1.32. Ikena Oncology has a one year low of $0.97 and a one year high of $1.94. The stock has a market cap of $69.01 million, a PE ratio of -2.23 and a beta of 0.50.</p>
<div class="lb-trans"><p>週五午盤交易中，納斯達克股票代碼：IKNA 的股票上漲了 $0.06，達到 $1.43。該公司交易了 445,143 股，較其平均交易量 411,726 股有所增加。該公司的 50 日移動平均線為 $1.31，200 日移動平均線為 $1.32。Ikena Oncology 的一年最低價為 $0.97，一年最高價為 $1.94。該股票的市值為 6901 萬美元，市盈率為-2.23，貝塔值為 0.50。</p>
</div><p>Ikena Oncology's stock is set to reverse split on Monday, July 28th. The 1-12 reverse split was announced on Friday, July 25th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, July 25th.</p>
<div class="lb-trans"><p>Ikena Oncology 的股票將於 7 月 28 日（星期一）進行反向拆分。1-12 的反向拆分於 7 月 25 日（星期五）宣佈。股東所持股份的數量將在 7 月 25 日（星期五）市場收盤後進行調整。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Separately, Wedbush reduced their price objective on shares of Ikena Oncology from $25.00 to $23.00 and set a &#34;neutral&#34; rating for the company in a research note on Friday.</p>
<div class="lb-trans"><p>另外，Wedbush 在週五的研究報告中將 Ikena Oncology 的目標股價從 $25.00 下調至 $23.00，並對該公司給予 “中性” 評級。</p>
</div><p><strong>Check Out Our Latest Research Report on IKNA</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 IKNA 的最新研究報告</strong></p>
</div><h2>Hedge Funds Weigh In On Ikena Oncology</h2>
<div class="lb-trans"><h2>對 Ikena Oncology 的對沖基金看法</h2>
</div><p>A hedge fund recently raised its stake in Ikena Oncology stock. Goldman Sachs Group Inc. raised its holdings in shares of Ikena Oncology, Inc. (NASDAQ:IKNA - Free Report) by 62.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund owned 76,464 shares of the company's stock after purchasing an additional 29,369 shares during the quarter. Goldman Sachs Group Inc. owned 0.16% of Ikena Oncology worth $98,000 as of its most recent filing with the Securities &amp; Exchange Commission. Hedge funds and other institutional investors own 75.00% of the company's stock.</p>
<div class="lb-trans"><p>一家對沖基金最近增加了對 Ikena Oncology 股票的持股。高盛集團在第一季度將其在 Ikena Oncology, Inc.（納斯達克股票代碼：IKNA - 免費報告）的持股增加了 62.4%，根據其最近向證券交易委員會提交的 13F 表格。該基金在本季度購買了額外的 29,369 股後，持有 76,464 股該公司的股票。高盛集團在其最近向證券交易委員會提交的文件中顯示，持有 Ikena Oncology 的股份佔 0.16%，價值 98,000 美元。對沖基金和其他機構投資者持有該公司 75.00% 的股份。</p>
</div><h2>About Ikena Oncology</h2>
<div class="lb-trans"><h2>關於 Ikena Oncology</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.</p>
<div class="lb-trans"><p>Ikena Oncology, Inc 是一家腫瘤學公司，專注於開發針對美國患者的差異化療法，旨在針對癌症生長、擴散和治療抵抗的節點。其主要項目是 IK-930，這是一種內部發現的、口服的、TEAD1 選擇性的 Hippo 通路小分子抑制劑。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Ikena Oncology</li>
<li>Consumer Discretionary Stocks Explained</li>
<li>Crypto Skeptics Can Still Win Big With These Risk-Limiting ETFs</li>
<li>The Risks of Owning Bonds</li>
<li>3 Discounted Steel Stocks You Can DCA Into Today</li>
<li>What is the MACD Indicator and How to Use it in Your Trading</li>
<li>Could Baker Hughes Be an Unlikely Winner in Drone Defense Boom?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Ikena Oncology</li>
<li>消費者可選股票解析</li>
<li>加密懷疑論者仍可通過這些風險限制 ETF 獲得豐厚回報</li>
<li>擁有債券的風險</li>
<li>3 只折扣鋼鐵股票，您今天可以進行定投</li>
<li>什麼是 MACD 指標以及如何在交易中使用它</li>
<li>貝克休斯可能在無人機防禦熱潮中成為意外贏家嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUtOQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=IKNA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ikena Oncology Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資$1,000 到 Ikena Oncology 嗎？</h2>
</div><p>Before you consider Ikena Oncology, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Ikena Oncology 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦購買，以便在更廣泛的市場注意到之前...而 Ikena Oncology 並不在名單上。</p>
</div><p>While Ikena Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Ikena Oncology 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Ikena Oncology（NASDAQ:IKNA）公佈了財報結果